ABCL Stock Recent News

If you aspire to one day topple entrepreneurial genius Elon Musk on the net wealth rankings through the equities market exclusively, you're obviously going to need to conduct heavy research on the stocks that can make you rich. However, you also want to be smart about this.

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q4 2022 Earnings Conference Call February 21, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chairman, Chief Executive Officer, and President Andrew Booth - Chief Financial Officer Conference Call Participants Tiago Fauth - Credit Suisse Andrea Tan - Goldman Sachs Gary Nachman - BMO Robyn Karnauskas - Truist Gaurav Goparaju - Berenberg Antonia Borovina - Bloom Burton Operator Good afternoon. And welcome to AbCellera's Full-Year 2022 Business Update Conference Call.

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -1,100% and 62.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.

VANCOUVER, British Columbia--( BUSINESS WIRE )--AbCellera (Nasdaq: ABCL) today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).

Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.

In this article, I will provide my valuation model for AbCellera, building on an article I wrote over a year ago. In the last year, many of my inputs I previously used have changed, given the greater transparency of the company throughout 2022. Some for the better, some for the worse.

While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific.

AbCellera reported its Q3 earnings on November 8th, solidly beating estimates on both the top and bottom lines. The company, in the days before the release, indicated that Regeneron has advanced its first GCPR target into preclinical development, further validating its platform.

AbCellera Biologics Inc (NASDAQ:ABCL ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chairman, Chief Executive Officer and President Andrew Booth - Chief Financial Officer Conference Call Participants Do Kim - Piper Sandler Gaurav Goparaju - Berenberg Capital Markets Stephen Willey - Stifel Financial Corp. Gary Nachman - BMO Capital Markets Antonia Borovina - Bloom Burton Operator Good afternoon. And welcome to AbCellera's Third Quarter 2022 Business Update Conference Call.